Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05922761 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

StatusRecruiting
PhasePhase 2
Started2024-05-31
View on ClinicalTrials.gov ↗

Amendment history

2026-06-08
Study Status, Contacts/Locations v8
Study sites5→6
2026-02-09
Study Status v7
Re-verified, no change to tracked fields
2025-06-03
Study Status, Contacts/Locations v6
Primary completion date2026-06-30→2027-06-30
Completion date2026-12-31→2027-12-31
Study sitescontacts updated at 1 of 5 sites
2024-08-14
Study Status, Contacts/Locations v5
Study sites4→5
2024-06-12
Study Status v4
Primary completion date2024-12-31→2026-06-30
Completion date2025-12-31→2026-12-31
Start date2024-01-02→2024-05-31
Show 3 earlier versions
2024-02-26
Study Status, Contacts/Locations v3
Study sites4 entries, revised
MassachusettsFred GeneralHutchinson HospitalCancer Center
2024-01-16
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-12→confirmed 2024-01-02
Study sitesdetails revised at 4 of 4 sites
2023-06-27
Study Status, Arms and Interventions, Outcome Measures v1
InterventionsAzithromycin (Drug), Belumosudil (Drug), Fluticasone (Drug), Prednisone (Drug)→Azithromycin (Drug), Belumosudil (Drug), Fluticasone (Drug), Montelukast (Drug), Prednisone (Drug)
Secondary endpointsdetails revised at 2 of 5 entries
2023-06-19
Original filing
The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: * Belumosudil (an immunotherapy) * Fluticasone (an intranasal corticosteroid) * Azithromycin (an antibiotic) * Montelukast (a leukotriene receptor antagonist) * Prednisone (a corticosteroid)
Trial Details
NCT Number NCT05922761
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Sanofi, National Heart, Lung, and Blood Institute (NHLBI)
Conditions Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
Enrollment 45 participants
Start Date 2024-05-31
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-10